Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens

Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens

Timothy L Comstock,1 Timothy W Morris,2 Lynne S Gearinger,2 Heleen H DeCory11Medical Affairs, 2Department of Microbiology and Sterilization Sciences, Bausch + Lomb, Rochester, NY, USAPurpose: Besifloxacin is a chlorofluoroquinolone approved for use in the treatment of bacterial conjunctivitis. This...

全面介绍

书目详细资料
Main Authors: Comstock TL, Morris TW, Gearinger LS, DeCory HH
格式: 文件
语言:English
出版: Dove Medical Press 2014-04-01
丛编:Clinical Optometry
在线阅读:http://www.dovepress.com/clinical-outcomes-with-besifloxacin-ophthalmic-suspension-06-in-the-tr-a16297

因特网

http://www.dovepress.com/clinical-outcomes-with-besifloxacin-ophthalmic-suspension-06-in-the-tr-a16297

相似书籍